Overall Technical outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Revenue projections:

Revenue projections for DXCM
DXCM's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 1.73800
forwardPE 25.96313
debtToEquity 54.93800
earningsGrowth 0.02600
revenueGrowth 0.11200
grossMargins 0.63424
operatingMargins 0.23975
trailingEps 2.57000
forwardEps 3.13483

The current ratio for DXCM is 1.738, indicating that the company can service its short-term debt using available cash and assets. This suggests DXCM has strong liquidity, with more than enough resources to meet its immediate financial commitments.
DXCM's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
DexCom, Inc.'s positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
DXCM's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that DXCM is likely to outperform its previous year's financial performance.

Price projections:

Price projections for DXCM
The stock price of DexCom, Inc. has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Insider Transactions:

Insider Transactions for DXCM

DXCM experienced 25 sell transactions with market price of 75.1752001953125 per share.1 purchases of DXCM were executed, with market price of 54.84000015258789.More sells than buys at DXCM's current price levels suggest a potential downside. If this selling trend persists, it could trigger further price declines, as increased selling often reflects investor pessimism about the stock's future prospects.

Recommendation changes over time:

Recommendations trend for DXCM

The recent buy bias from analysts suggests DXCM is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, DXCM appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.